Pharmacoeconomic comparison between chronochemotherapy and folfox regimen in the treatment of patients with metastatic colorectal cancer: A cost-minimization study

Tumori

Volumn 90, Issue 1, 2004, Pages 44-49

  Tampellini, Marco ^a   Bitossi, Raffaella ^a   Brizzi, Maria Pia ^a   Saini, Andrea ^a   Tucci, Marcello ^a   Alabiso, Irene ^a   Dogliotti, Luigi ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Chronotherapy; FOLFOX regimen; Metastatic colorectal cancer; Pharmacoeconomy

Indexed keywords

ALIZAPRIDE; ANTIEMETIC AGENT; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LOPERAMIDE; OXALIPLATIN;

ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CHRONOTHERAPY; COLORECTAL CARCINOMA; CONTROLLED STUDY; COST MINIMIZATION ANALYSIS; DIARRHEA; DRUG COST; DRUG DELIVERY SYSTEM; FEBRILE NEUTROPENIA; HEALTH CARE COST; HUMAN; INTERMETHOD COMPARISON; METASTASIS; MOUTHWASH; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PUMP; REHYDRATION; SIDE EFFECT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 2142829437     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160409000111     Document Type: Article

References (31)

1. Negri A, La Vecchia C, Decarli A: Cancer mortality in Italy, 1998. Tumori, 87: 290-298, 2001.
2. Levi F, Lucchini F, Negri E, Boyle P, La Vecchia C: Mortality from major cancer sites in the European Union, 1955-1998. Ann Oncol, 14: 490-495, 2003.
3. Lokich J, Anderson N: Infusional chemotherapy: historical evolution and future development at the cancer center of Boston. Cancer Invest, 13: 202-226, 1995.
4. Lokich J, Anderson N: Dose intensity for bolus versus infusion chemotherapy administration: review of the literature for 27 anti-neoplastic agents. Ann Oncol, 8: 15-25, 1997.
5. Bleiberg H, Hendlisz: Advanced colorectal cancer treatment in Europe: what have we achieved? Anti-Cancer Drugs, 13: 461-471, 2002.
6. De Gramont A, Louvet C, Andre T, Tournigand C, Krulik M: A review of GERCOD trials of bimonthly leucovorin plus 5-fluorouracil 48-h continuous infusion in advanced colorectal cancer: evolution of a regimen. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD). Eur J Cancer, 34: 619-626, 1998.
7. De Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, De Braud F, Wilson C, Morvan F, Bonetti A: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol, 18: 2938-2947, 2000.
8. Maindrault-Goebel F, de Gramont A, Louvet C, Andre T, Carola E, Gilles V, Lotz JP, Tournigand C, Mabro M, Molitor JL, Artru P, Izrael V, Krulik M: Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR). Ann Oncol, 11: 1477-1483, 2000.
9. Lévi F, Misset JL, Brienza S, Adam R, Metzger G, Itzhaki M, Caussanel JP, Kunstlinger F, Lecouturier S, Descorps-Declere A, Jasmin C, Bismuth H, Reinberg A: A chrono-pharmacologic phase-II clinical trial with 5-fluorouracil, folinic acid and oxaliplatin using an ambulatory multichannel programmable pump. High anti-tumor effectiveness against metastatic colorectal cancer. Cancer, 69: 893-900, 1992.
10. Levi F, Zidani R, Vannetzel JM, Perpoint B, Focan C, Faggiuolo R, Chollet P, Garufi C, Itzhaki M, Dogliotti L, Iacobelli S, Adam R, Kunstlinger F, Gastiaburu J, Bismuth H, Jasmin C, Misset JL: Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J Natl Cancer Inst, 86: 1608-1617, 1994.
11. Lévi F, Zidani R, Misset JL: Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet, 350: 681-686, 1997.
12. Lévi F, Zidani R, Brienza S, Dogliotti L, Perpoint B, Rotarski M, Letourneau Y, Llory JF, Chollet P, Le Rol A, Focan C: A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma. Cancer, 85: 2532-2540, 1999.
13. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y, Coudert B, Bertheault-Cvitkovic F, Larregain-Fournier D, Le Rol A, Walter S, Adam R, Misset JL, Lévi F: Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol, 18: 136-147, 2000.
14. André T, Bensmaine MA, Louvet C, Francois E, Lucas V, Desseigne F, Beerblock K, Bouché O, Carola E, Merrouche Y, Morvan F, Dupont-André G, De Gramont A: Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol, 17: 3560-3568, 1999.
15. Bertheault-Cvitkovic F, Jami A, Ithzaki M, Deprés-Brummer P, Brienza S, Adam R, Kunstlinger F, Bismuth H, Misset JL, Lévi F: Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer. J Clin Oncol, 14: 2950-2958, 1996.
16. Lucioni C, Mazzi S, Vanoverbeke N, Annemans L, Botta G, Rocchi M: Il costo degli effetti collaterali nella chemioterapia del cancro metastatico del colon retto: trattamento con UFT vs 5-FU. In: Pharmacoeconomic issues in oncology, Gerardo G (Ed), pp 1-17, Adis International, Milan, 2002.
17. Ozer H, Armitage JO, Bennett CL, Crawford J, Demetri GD, Pizzo PA, Schiffer CA, Smith TJ, Somlo G, Wade JC, Wade JL 3rd, Winne RJ, Wozniak AJ, Somerfield MR; American Society of Clinical Oncology: 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology growth factors expert panel. J Clin Oncol, 18: 3558-3585, 2000.
18. Mitchell PL, Morland B, Stevens MC, Dick G, Easlea D, Meyer LC, Pinkerton CR: Granulocyte colony-stimulating factor in established febrile neutropenia: a randomized study of pediatric patients. J Clin Oncol, 15: 1163-1170, 1997.
19. Vellenga E, Uyl-de Groot CA, de Wit R, Keizer HJ, Lowenberg B, ten Haaft MA, de Witte TJ, Verhagen CA, Stoter GJ, Rutten FF, Mulder NH, Smid WM, de Vries EG: Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia. J Clin Oncol, 14: 619-627, 1996.
20. Mayordomo JI, Rivera F, Diaz-Puente MT, Lianes P, Colomer R, Lopez-Brea M, Lopez E, Paz-Ares L, Hitt R, Garcia-Ribas I: Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. J Natl Cancer Inst, 87: 803-808, 1995.
21. Mathe G, Kidani Y, Triana K, Brienza S, Ribaud P, Goldschmidt E, Ecstein E, Despax R, Musset M, Misset JL: A phase I trial of trans-diaminocyclohexane oxalato-platinum (I-OHP). Biomed Pharmacother, 40: 372-376, 1986.
22. Wasserman E, Cuvier C, Lokiec F, Goldwasser F, Kalla S, Méry-Mignard D, Ouldkaci M, Besmaine A, Dupont-André G, Mahjoubi M, Marty M, Misset JL, Cvitkovic E: Combination of oxaliplatin pus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics. J Clin Oncol, 17: 1751-1759, 1999.
23. Dale DC: Colony-stimulating factors for the management of neutropenia in cancer patients. Drugs, 62 (Suppl 1): 1-15, 2002.
24. Maindrault-Goebel F, de Gramont A, Louvet C, Andre T, Carola E, Mabro M, Artru P, Gilles V, Lotz JP, Izrael V, Krulik M: Oncology Multidisciplinary Research Group (GERCOR): High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). Eur J Cancer, 37: 1000-1005, 2001.
25. Louvet C, De Gramont A, Tournigand C, Artru P, Maindrault-Goebel F, Krulik M: Correlation between progression free survival and response rate in patients with metastatic colorectal carcinoma. Cancer, 91: 2033-2038, 2001.
26. Giacchetti S, Itzhaki M, Gruia G, Adam R, Zidani R, Kunstlinger F, Brienza S, Alafaci E, Bertheault-Cvitkovic F, Jasmin C, Reynes M, Bismuth H, Misset JL, Levi F: Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol, 10: 663-669, 1999.
27. Neymark N, Adriaenssen I: The costs of managing patients with advanced colorectal cancer in 10 different European centres. Eur J Cancer, 35: 1789-1795, 1999.
28. Levy-Piedbois C, Durand-Zaleski I, Juhel H, Schmitt C, Bellanger A, Piedbois P: Cost-effectiveness of second-line treatment with irinotecan or infusional 5-fluorouracil in metastatic colorectal cancer. Ann Oncol, 11: 157-161, 2000.
29. Ross P, Heron J, Cunningham D: Cost of treating advanced colorectal cancer: a retrospective comparison of treatment regimens. Eur J Cancer, 32A: S13-S17, 1996.
30. Sculpher M, Palmer MK, Heyes A: Costs incurred by patients undergoing advanced colorectal cancer therapy. A comparison of raltitrexed and fluorouracil plus folinic acid. Pharmacoeconomics, 17: 361-370, 2000.
31. Focan C: Pharmaco-economic comparative evaluation of combination chronotherapy vs standard chemotherapy for colorectal cancer. Chronobiol Int, 19: 289-297, 2002.